<DOC>
	<DOCNO>NCT02143882</DOCNO>
	<brief_summary>The Department Health recently announce implementation annual vaccination age 18 year , live attenuate influenza vaccine ( LAIV ) , deliver nasal spray . This study seek primarily measure antibody responses LAIV vaccination three subsequent year involve six blood sample , six dry blood spot ( take end blood sample needle ) six oral fluid sample - three week vaccination year . These sample allow u ass immune system respond vaccination term antibody present .</brief_summary>
	<brief_title>A Phase III/IV Open-label Study Immunogenicity Safety Single Dose Live Attenuated Influenza Vaccine ( LAIV ) ( FluenzTM ) Each Three Successive Years Children naïve , Previous Receipt AS03B Adjuvanted H1N1 ( 2009 ) Influenza Vaccine ( Pandemrix ™ ) .</brief_title>
	<detailed_description>The Department Health recently announce implementation annual vaccination age 18 year , live attenuate influenza vaccine ( LAIV ) , deliver nasal spray . The programme begin influenza season , September 2013 , child age 24 year age , old child include influenza season 2014 . Therefore study seek primarily measure antibody responses LAIV vaccination three subsequent year involve six blood sample , six dry blood spot ( take end blood sample needle ) six oral fluid sample - three week vaccination year . These sample allow u ass immune system respond vaccination term antibody present . The study specifically recruit child previous receipt Pandemrix , pandemic influenza vaccine , naïve pandemic influenza vaccination , allow comparison response LAIV group . The sample size require answer primary objective study 200 evaluable child per group . As study conduct three year recruitment target 500 child across two group allow expect attrition number time . The investigator also assess well vaccine tolerate participant therefore ask complete health diary week follow vaccination . They ask record symptom , investigator elicit line information Summary Product Characteristics ( SPC ) well illnesses visit GP hospital .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Parent/legal guardian give write informed consent participation child study . Male female age 4 year ( +364 day ) 8 year ( +364 day ) day consent . Documented prior receipt Pandemrix , evidence medical note never pandemic influenza vaccine . Absolute exclusion criterion . The participant may enter study ANY follow apply : From Fluenz Summary Product Characteristics ( SPC ) : Hypersensitivity active substance , excipients ( e.g . gelatin; see appendix 1 ) , gentamicin ( possible trace residue ) , eggs egg protein ( e.g . ovalbumin ) . Children adolescents clinically immunodeficient due condition immunosuppressive therapy : acute chronic leukaemias; lymphoma; symptomatic HIV infection; cellular immune deficiencies; highdose corticosteroid . FLUENZ contraindicate use individual asymptomatic HIV infection; individual receive topical/inhaled corticosteroid lowdose systemic corticosteroid receive corticosteroid replacement therapy , e.g . adrenal insufficiency . Children adolescents young 18 year age receive salicylate therapy association Reye 's syndrome salicylates wildtype influenza infection . Study specific exclusion : Any contraindication vaccination specify `` Green Book '' Immunisation Infectious Disease , HMSO . know bleed diathesis ( condition may associate prolonged bleeding time ) . Any significant condition circumstance , opinion investigator , may either put participant risk participation study , may influence result study , participant 's ability participate study . *Temporary Exclusion Criteria From SPC : • The concurrent use FLUENZ antiviral agent active influenza A and/or B virus evaluate . However , base upon potential influenza antiviral agent reduce effectiveness FLUENZ , recommend administer vaccine 48 hour cessation influenza antiviral therapy . Administration influenza antiviral agent within two week vaccination may affect response vaccine . Because information SPC , child give medication administration LAIV would delay specify . Study specific : Fever ( sublingual temperature ≥ 38°C ) Received blood blood product within past 12 week .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Live attenuate influenza vaccine</keyword>
	<keyword>fluenz</keyword>
	<keyword>pandemrix</keyword>
	<keyword>pandemic influenza vaccine</keyword>
	<keyword>immunogenicity</keyword>
</DOC>